

Achondroplasia (FGFR3) 2 Mutations, Fetal

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	Unknown
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Achondroplasia PCR Fetal Specimen	Cultured Amnio		
Achondroplasia PCR, Fetal Interp	Negative		
	Indication for testing: Rule out achondroplasia. Negative: The fibroblast growth factor receptor (FGFR) 3 gene mutations, G1138A (also known as c.1138G>A) and G1138C (also known as c.1138G>C), were not present. Therefore, this individual is unlikely to be affected with achondroplasia. Rarely, an affected person may have another mutation not detectable by this assay.		
	This result has been reviewed and approved by		
	BACKGROUND INFORMATION: Achondroplasia (FGFR3) 2 Mutations, Fetal CHARACTERISTICS: Short stature with disproportionately short arms and legs, a large head, usually normal life span and intelligence; increased risk for death in infancy from compression of spinal cord and/or upper airway obstruction. INCIDENCE: 1:25,000 INHERITANCE: Autosomal dominant; 80 percent arise from de novo mutations PENETRANCE: 100 percent CAUSE: Pathogenic FGFR3 gene mutation CLINICAL SENSITIVITY: >99 percent METHODOLOGY: Polymerase Chain Reaction (PCR)/Fluorescent Monitoring/Fragment Analysis. ANALYTICAL SENSITIVITY AND SPECIFICITY: >99 percent LIMITATIONS: Mutations other than c.1138G>A and c.1138G>C will not be detected. Diagnostic errors can occur due to rare sequence variants or maternal cell contamination of the fetal specimen.		
	This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.		
	Counseling and informed consent are recommended for genetic testing. Consent forms are available online.		
Maternal Contamination Study Fetal Spec	Fetal Cells		

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:



Single fetal genotype present; no maternal cells present. Fetal and maternal samples were tested using STR markers to rule out maternal cell contamination.

Maternal Contam Study, Maternal Spec

Whole Blood

VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
Achondroplasia PCR Fetal Specimen	24-019-112266	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Achondroplasia PCR, Fetal Interp	24-019-112266	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Maternal Contamination Study Fetal Spec	24-019-112266	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Maternal Contam Study, Maternal Spec	24-019-112266	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruptab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 24-019-112266 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 2 | Printed: 2/2/2024 8:39:37 AM 4848